{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:25:02Z","timestamp":1787181902878,"version":"build-2736575974"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119795","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:59:40Z","timestamp":1784843980000},"page":"119795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer"],"prefix":"10.1016","volume":"202","author":[{"given":"Yeji","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Hoon","family":"Choung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minki","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Sup","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngju","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-hyun","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somin","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Suep","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9326-5734","authenticated-orcid":false,"given":"Jun-Hyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3670-386X","authenticated-orcid":false,"given":"Hong-Ki","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7937-1626","authenticated-orcid":false,"given":"Young-Guk","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheong-Weon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119795_bib1","first-page":"721","article-title":"Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives","volume":"30","author":"Wang","year":"2023","journal-title":"Breast Cancer"},{"key":"10.1016\/j.biopha.2026.119795_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","article-title":"Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","volume":"22","author":"Ye","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2026.119795_bib3","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/cells12040659","article-title":"Doxorubicin\u2014an agent with multiple mechanisms of anticancer activity","volume":"12","author":"Kciuk","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2026.119795_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101205","article-title":"Doxorubicin and other anthracyclines in cancers: activity, chemoresistance and its overcoming","volume":"93","author":"Mattioli","year":"2023","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.biopha.2026.119795_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12964-023-01077-5","article-title":"Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy","volume":"21","author":"Shi","year":"2023","journal-title":"Cell. Commun. Signal."},{"key":"10.1016\/j.biopha.2026.119795_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5939-z","article-title":"Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model","volume":"19","author":"Christowitz","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2026.119795_bib7","doi-asserted-by":"crossref","first-page":"760","DOI":"10.7150\/ijbs.65258","article-title":"Underlying the mechanisms of doxorubicin-induced acute cardiotoxicity: oxidative stress and cell death","volume":"18","author":"Kong","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biopha.2026.119795_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111708","article-title":"Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management","volume":"139","author":"Rawat","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2026.119795_bib9","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.5530\/ijper.53.3s.91","article-title":"Experimental data of fabricated co-crystals of doxorubicin HCl with flavonoids","volume":"53","author":"Laxmi","year":"2019","journal-title":"Indian. J. Pharm. Educ. Res."},{"key":"10.1016\/j.biopha.2026.119795_bib10","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/nnm-2017-0007","article-title":"Doxorubicin-loaded liposomes: enhancing the oral bioavailability by modulation of physicochemical characteristics","volume":"12","author":"Daeihamed","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.biopha.2026.119795_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2021.127351","article-title":"Effective drug delivery system based on hydrophobin and halloysite clay nanotubes for sustained release of doxorubicin","volume":"628","author":"Wang","year":"2021","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.biopha.2026.119795_bib12","first-page":"1","article-title":"Overview on the side effects of doxorubicin","volume":"10","author":"Ajaykumar","year":"2020","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"10.1016\/j.biopha.2026.119795_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.biopha.2026.119795_bib14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119795_bib15","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s13346-018-0551-3","article-title":"Metastatic and triple-negative breast cancer: challenges and treatment options","volume":"8","author":"Al-Mahmood","year":"2018","journal-title":"Drug. Deliv. Transl. Res."},{"key":"10.1016\/j.biopha.2026.119795_bib16","first-page":"1609","article-title":"A perspective on anti-EGFR therapies targeting triple-negative breast cancer","volume":"6","author":"Nakai","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119795_bib17","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.18632\/oncotarget.12284","article-title":"Triple-negative breast cancer: is there a treatment on the horizon?","volume":"8","author":"Yao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119795_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121852","article-title":"Enhanced stability and oral bioavailability of erlotinib by solid self nano emulsifying drug delivery systems","volume":"622","author":"Jain","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119795_bib19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.5483\/BMBRep.2017.50.3.189","article-title":"Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells","volume":"50","author":"Oh","year":"2017","journal-title":"BMB Rep."},{"key":"10.1016\/j.biopha.2026.119795_bib20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2174\/1568026620666200303123102","article-title":"Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors","volume":"20","author":"Sabbah","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119795_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104683","article-title":"Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer","volume":"153","author":"Deepak","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2026.119795_bib22","first-page":"957","article-title":"Mechanisms of chemotherapy resistance in triple-negative breast cancer\u2014how we can rise to the challenge","volume":"42","author":"Nedeljkovi\u0107","year":"2019","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.biopha.2026.119795_bib23","series-title":"Profiles of Drug Substances, Excipients and Related Methodology","first-page":"93","article-title":"Erlotinib","author":"Abdelgalil","year":"2020"},{"key":"10.1016\/j.biopha.2026.119795_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamaoncol.2015.4364","article-title":"Erlotinib and the risk of oral cancer: the erlotinib prevention of oral cancer (EPOC) randomized clinical trial","volume":"2","author":"William","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2026.119795_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.phymed.2017.11.003","article-title":"Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib","volume":"37","author":"Efferth","year":"2017","journal-title":"Phytomedicine"},{"key":"10.1016\/j.biopha.2026.119795_bib26","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jtho.2016.11.2236","article-title":"Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non\u2013small cell lung cancer","volume":"12","author":"Ding","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.biopha.2026.119795_bib27","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jconrel.2020.07.003","article-title":"A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer","volume":"326","author":"Jain","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119795_bib28","first-page":"466","article-title":"Development of solid self-emulsifying formulation for improving the oral bioavailability of erlotinib","volume":"17","author":"Truong","year":"2016","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119795_bib29","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1080\/03639045.2017.1326931","article-title":"Nanoparticulation improves bioavailability of Erlotinib","volume":"43","author":"Yang","year":"2017","journal-title":"Drug. Dev. Ind. Pharm."},{"key":"10.1016\/j.biopha.2026.119795_bib30","first-page":"45","article-title":"Skin rash in patients treated with neoadjuvant erlotinib (Tarceva) in resectable non-small cell lung cancer: Predictor for tumor response and survival","volume":"5","author":"van Gool","year":"2017","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.biopha.2026.119795_bib31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2016.03.001","article-title":"Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy","volume":"229","author":"He","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119795_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.colsurfb.2018.09.047","article-title":"Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model","volume":"173","author":"Lakkadwala","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biopha.2026.119795_bib33","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ijpharm.2017.07.085","article-title":"Sequential delivery of erlotinib and doxorubicin for enhanced triple negative Breast cancer treatment using polymeric nanoparticle","volume":"530","author":"Zhou","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119795_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-021-01160-4","article-title":"Rhamnolipid-coated W\/O\/W double emulsion nanoparticles for efficient delivery of doxorubicin\/erlotinib and combination chemotherapy","volume":"19","author":"Lee","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.biopha.2026.119795_bib35","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.talanta.2011.08.034","article-title":"Analysis of anticancer drugs: a review","volume":"85","author":"Nussbaumer","year":"2011","journal-title":"Talanta"},{"key":"10.1016\/j.biopha.2026.119795_bib36","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3390\/biomedicines9091143","article-title":"Rutaecarpine increases anticancer drug sensitivity in drug-resistant cells through MARCH8-dependent ABCB1 degradation","volume":"9","author":"Zou","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119795_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10213","article-title":"Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles","volume":"6","author":"Schlich","year":"2021","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119795_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba1028","article-title":"Ionizable lipid nanoparticles for in utero mRNA delivery","volume":"7","author":"Riley","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2026.119795_bib39","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/0883911516675367","article-title":"A novel biocompatible antibacterial product: Nanoliposomes loaded with poly (hexamethylene biguanide chloride)","volume":"32","author":"Ahani","year":"2017","journal-title":"J. Bioact. Compat. Polym."},{"key":"10.1016\/j.biopha.2026.119795_bib40","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3390\/foods10030492","article-title":"Encapsulation of Berberis vulgaris anthocyanins into nanoliposome composed of rapeseed lecithin: A comprehensive study on physicochemical characteristics and biocompatibility","volume":"10","author":"Homayoonfal","year":"2021","journal-title":"Foods"},{"key":"10.1016\/j.biopha.2026.119795_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.579536","article-title":"Insight into nanoliposomes as smart nanocarriers for greening the twenty-first century biomedical settings","volume":"8","author":"Aguilar-P\u00e9rez","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119795_bib42","doi-asserted-by":"crossref","first-page":"23875","DOI":"10.1021\/acsomega.2c02594","article-title":"Development of Biodegradable\/Biocompatible Nanoliposome-Encapsulated Antimicrobial Essential Oils for Topical Creams and Gels","volume":"7","author":"Al-Ogaidi","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.biopha.2026.119795_bib43","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s13346-017-0405-4","article-title":"Evaluation of propylene glycol nanoliposomes containing curcumin on burn wound model in rat: biocompatibility, wound healing, and anti-bacterial effects","volume":"7","author":"Kianvash","year":"2017","journal-title":"Drug. Deliv. Transl. Res."},{"key":"10.1016\/j.biopha.2026.119795_bib44","doi-asserted-by":"crossref","first-page":"26007","DOI":"10.1039\/C5RA01881A","article-title":"Surface characteristics, corrosion resistance and MG63 osteoblast-like cells attachment behaviour of nano SiO2\u2013ZrO2 coated 316L stainless steel","volume":"5","author":"Srinivasan","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.biopha.2026.119795_bib45","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1021\/acs.bioconjchem.6b00437","article-title":"Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer?","volume":"27","author":"Nakamura","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.biopha.2026.119795_bib46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1039\/D2RA06888E","article-title":"Effects of morphology and size of nanoscale drug carriers on cellular uptake and internalization process: a review","volume":"13","author":"Zhang","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.biopha.2026.119795_bib47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1039\/C6NR06701H","article-title":"Cationic switchable lipids: pH-triggered molecular switch for siRNA delivery","volume":"9","author":"Viricel","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.biopha.2026.119795_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2024.102506","article-title":"Strategies and mechanisms for endosomal escape of therapeutic nucleic acids","volume":"81","author":"Grau","year":"2024","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.biopha.2026.119795_bib49","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1038\/s41467-019-12906-y","article-title":"An anionic, endosome-escaping polymer to potentiate intracellular delivery of cationic peptides, biomacromolecules, and nanoparticles","volume":"10","author":"Evans","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119795_bib50","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.2147\/IJN.S86467","article-title":"Combination of glycosphingosomes and liposomal doxorubicin shows increased activity against dimethyl-\u03b1-benzanthracene-induced fibrosarcoma in mice","volume":"10","author":"Khan","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119795_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2017.09.071","article-title":"Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid","volume":"534","author":"Dora","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119795_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1025013","article-title":"Formulation development of lipid polymer hybrid nanoparticles of doxorubicin and its in-vitro, in-vivo and computational evaluation","volume":"14","author":"Shafique","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119795_bib53","article-title":"Erlotinib-functionalized dextran derivatives enable self-assembly of redox-responsive paclitaxel dimers for lung Cancer treatment after Intratracheal delivery","volume":"326","author":"Wu","year":"2025","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.biopha.2026.119795_bib54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","article-title":"Tumor targeting via EPR: Strategies to enhance patient responses","volume":"130","author":"Golombek","year":"2018","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.biopha.2026.119795_bib55","article-title":"Ionizable Lipid Containing Nanocarriers for Antimicrobial Agent Delivery","volume":"4","author":"Yu","year":"2024","journal-title":"Small Sci."},{"key":"10.1016\/j.biopha.2026.119795_bib56","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1039\/D3TB02766J","article-title":"Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders","volume":"12","author":"Chu","year":"2024","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.biopha.2026.119795_bib57","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1039\/D4NR04508D","article-title":"More than a delivery system: the evolving role of lipid-based nanoparticles","volume":"17","author":"Karmaker","year":"2025","journal-title":"Nanoscale"},{"key":"10.1016\/j.biopha.2026.119795_bib58","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00232-022-00263-9","article-title":"Cholesterol stiffening of lipid membranes","volume":"255","author":"Doole","year":"2022","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.biopha.2026.119795_bib59","first-page":"2042","article-title":"pH sensing by lipids in membranes: The fundamentals of pH-driven migration, polarization and deformations of lipid bilayer assemblies","volume":"2018","author":"Angelova","year":"1860","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.biopha.2026.119795_bib60","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2022.06.064","article-title":"Mannosylated poly (acrylic acid)-coated mesoporous silica nanoparticles for anticancer therapy","volume":"349","author":"Lee","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119795_bib61","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3390\/pharmaceutics15071920","article-title":"Reduction of doxorubicin-induced cardiotoxicity by Co-administration of smart liposomal doxorubicin and free quercetin: in vitro and in vivo studies","volume":"15","author":"Dorostkar","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119795_bib62","first-page":"205","article-title":"Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil","volume":"10","author":"Al Asmari","year":"2016","journal-title":"Drug. Des. Devel. Ther."},{"key":"10.1016\/j.biopha.2026.119795_bib63","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.msec.2012.12.004","article-title":"Characterization of 17-4 PH stainless steel foam for biomedical applications in simulated body fluid and artificial saliva environments","volume":"33","author":"Mutlu","year":"2013","journal-title":"Mater. Sci. Eng. C."},{"key":"10.1016\/j.biopha.2026.119795_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2020.102320","article-title":"Synergistic co-loading of vincristine improved chemotherapeutic potential of pegylated liposomal doxorubicin against triple negative breast cancer and non-small cell lung cancer","volume":"31","author":"Ghosh","year":"2021","journal-title":"Nanomed. NBM"},{"key":"10.1016\/j.biopha.2026.119795_bib65","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.apsb.2021.02.019","article-title":"Exploration and insights into the cellular internalization and intracellular fate of amphiphilic polymeric nanocarriers","volume":"11","author":"Mazumdar","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2026.119795_bib66","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.3390\/ijms26083820","article-title":"Co-Encapsulation of Multiple Antineoplastic Agents in Liposomes by Exploring Microfluidics","volume":"26","author":"Asghar","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119795_bib67","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbcan.2013.12.002","article-title":"Doxorubicin, DNA torsion, and chromatin dynamics","volume":"1845","author":"Yang","year":"2014","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119795_bib68","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119795_bib69","article-title":"Enhanced permeability and retention effect: A key facilitator for solid tumor targeting by nanoparticles","volume":"39","author":"Shinde","year":"2022","journal-title":"Photo Photodyn. Ther."},{"key":"10.1016\/j.biopha.2026.119795_bib70","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.biopha.2026.119795_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116699","article-title":"Acid-sensitive prodrugs; a promising approach for site-specific and targeted drug release","volume":"276","author":"Nazli","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119795_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115195","article-title":"Unlocking the mitochondria for nanomedicine-based treatments: overcoming biological barriers, improving designs, and selecting verification techniques","volume":"207","author":"Pegoraro","year":"2024","journal-title":"Adv. Drug. Deliv. Rev."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:52:19Z","timestamp":1787179939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226008310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":72,"alternative-id":["S0753332226008310"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119795","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119795","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119795"}}